

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/760,149	01/12/2001	Joseph Kevin Gogerty	1331	2360
27142	7590 10/03/2003		EXAM	INER
MCKEE, VOORHEES & SEASE, P.L.C. ATTN: PIONEER HI-BRED			FOX, DAVID T	
801 GRAND AVENUE, SUITE 3200			ART UNIT	PAPER NUMBER
DES MOINE	S, IA 50309-2721	1638		

DATE MAILED: 10/03/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
Advisory Action	09/760,149	GOGERTY, JOSEPH KEVIN				
	Examiner	Art Unit				
	David T. Fox	1638				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address						
THE REPLY FILED 27 August 2003 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. Therefore, further action by the applicant is required to avoid abandonment of this application. A proper reply to a final rejection under 37 CFR 1.113 may only be either: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114.						
PERIOD FOR REPLY [check either a) or b)]						
a) The period for reply expires <u>3</u> months from the mailing date of the final rejection.						
b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f). Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
1. A Notice of Appeal was filed on Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal.						
2. The proposed amendment(s) will not be entered because:						
(a) 🔯 they raise new issues that would require further consideration and/or search (see NOTE below);						
(b) they raise the issue of new matter (see Note below);						
(c) they are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or						
(d) 🔲 they present additional claims without canceling a corresponding number of finally rejected claims.						
NOTE: See Continuation Sheet.						
3. Applicant's reply has overcome the following rejection(s):						
4. Newly proposed or amended claim(s) <u>58-61,63-71 and 73-80</u> would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).						
5.⊠ The a) affidavit, b) exhibit, or c) request for reconsideration has been considered but does NOT place the application in condition for allowance because: <u>it relies upon the amendment which was not entered</u> .						
6. The affidavit or exhibit will NOT be considered because it is not directed SOLELY to issues which were newly raised by the Examiner in the final rejection.						
7.⊠ For purposes of Appeal, the proposed amendment(s) a)⊠ will not be entered or b)☐ will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended.						
The status of the claim(s) is (or will be) as follows:						
Claim(s) allowed: 1,58-61,63-71 and 73-80.						
Claim(s) objected to:						
Claim(s) rejected: <u>62,72,81-87</u> .						
Claim(s) withdrawn from consideration:						
3.☐ The proposed drawing correction filed on is a)☐ approved or b)☐ disapproved by the Examiner.						
9. Note the attached Information Disclosure Statement(s)(PTO-1449) Paper No(s)						
10. Other:						

Continuation Sheet (PTOL-303) 09/760,149

Application No.

Continuation of 2. NOTE: New issues: Amendment does not comply with revised 37 CFR 1.121 because it does not indicate the status of all of the originally filed claims, namely claims 3, 11-14, 17-20, 22, 30-36 and 44-49. Furthermore, a new 112 second paragraph issue is raised by claims 81-82 and 86-87 re "a 5% significance level" which is confusing, since there is only one 5% significance level, not one of several, as implied by "a". Claim 62 is also indefinite in its recitation of "the tissue culture" which lacks antecedent basis in dependent claim 58; the claim should depend upon claim 60. Claim 72 is also indefinite in its recitation of "transgene comprises a transgene encoding" which is awkward. Claim 86 is indefinite in its recitation of "introducing modified...metabolism" which is awkward. Enablement rejections are also raised by claims drawn to the introduction of a metabolic pathway...

> DAVID T. FOX PRIMARY EXAMINER GROUP 180-/638 Jackel) (